3 results
Approved WMORecruiting
To assess the feasibility of using a subtherapeutic dose of piracetam as a marker of adherence to therapy by determining whether this subtherapeutic dose produces a detectable concentration in the urine
Approved WMOCompleted
The aim of this phase IVI, randomized, open-label study is to compare the efficacy of cabazitaxel versus an AR targeted agent, in patients previously treated with docetaxel and likely to have primary resistance to AR targeted agents.
Approved WMOCompleted
We will investigate how safe the study device DV3395-C1 is when it is taken in by healthy participants. We will also look at the passage (i.e., gastrointestinal transit time) and activation of the study device. For this, we will see if the deviceā¦